© Provided by Xinhua HAIKOU, March 31 (Xinhua) Another 39 drugs were selected in the new round of a bulk-buying program endorsed by the Chinese gove
An advisory committee from the U.S. Food and Drug Administration (FDA) has voted in favor of approving a new drug application for Pfizer’s COVID pill Paxlovid even as potential drug interaction risks were highlighted during the committee meeting.
China National Healthcare Security Administration NHSA published 2022 National Reimbursement Drug List 2022 NRDL, implementing comparable level of pricing discounts to those seen in 2021. Out of 147 drugs negotiated, 121 were successfully added to 2022 NRDL, including 91 exclusive.